Study of UBT251 injection for chronic kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an investigational injection called UBT251 for people with chronic kidney disease who are overweight. It aims to see if it can reduce protein in the urine and help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old with a BMI of 24 or higher.
- Your kidney function is moderately reduced (eGFR between 45 and 90).
- You have high levels of protein in your urine (UACR between 300 and 5000).
- You have not used GLP-1 agonists or similar weight-loss drugs in the last 3 months.
- You do not have certain kidney diseases (like lupus nephritis or polycystic kidney disease) or a history of pancreatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests HRS-7535, a new oral tablet that may help protect kidneys in people with chronic kidney disease. GLP-1 medications were originally developed for diabetes but may also benefit kidney function and overall health.
This study tests a new drug called IGT-303 for people with chronic kidney disease caused by type 2 diabetes. It aims to see if the drug is safe and can help protect kidney function.
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
This trial tests a medication called EC5026 in people with and without chronic kidney disease (CKD) to see how the body handles it. It helps understand if dose adjustments are needed for people with impaired kidney function.
This study tests a new injection (UBT251) to help people lose weight and improve weight-related health problems. You may qualify if you're overweight or obese and have tried diet and exercise for at least 3 months without much success.
This trial tests how a new drug called GZR18 (given as an injection) affects the body in people with different levels of kidney function. It aims to find the right dose and check for side effects, which could help guide treatment for people with kidney issues.
Hear when a new Obesity &Amp; Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.